[1] WORLD HEALTH ORGANIZATION.Global tuberculosis report 2025[EB/OL]. (2025-11-12)[2025-12-17]. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2025. [2] 国家疾病预防控制局, 中华人民共和国国家卫生健康委员会, 中华人民共和国国家发展和改革委员会. 全国结核病防治规划(2024—2030年)[J/CD]. 新发传染病电子杂志, 2025, 10(1): 94-96. [3] LI T, DU X, KANG J, et al.Patient, Diagnosis, and Treatment Delays Among Tuberculosis Patients Before and During COVID-19 Epidemic - China, 2018-2022[J]. China CDC Wkly, 2023, 5(12): 259-265. [4] WORLD HEALTH ORGANIZATION. the End TB Strategy[EB/OL]. (2015-08-16)[2025-12-17]. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/the-end-tb-strategy. [5] WORLD HEALTH ORGANIZATION. WHO consolidated guidelines on tuberculosis. Module 2: screening-systematic screening for tuberculosis disease[EB/OL]. (2021-03-22)[2025-12-17]. https://www.who.int/publications/i/item/9789240022676. [6] ESMAIL H, MILLER C, FALZON D, et al.Scaling-up symptom-agnostic, community-wide screening toward global tuberculosis elimination: opportunities, challenges, and lessons from history[J]. Int J Infect Dis, 2025, 155: 107875. [7] 中国疾病预防控制中心结核病控制中心. 创建无结核社区行动方案[EB/OL]. (2024-05-16) https://tb.chinacdc.cn/zgjhw/fzyw/guihua/202405/P020240516529342900427.pdf. [8] RICHARDS AS, SOSSEN B, EMERY JC, et al.Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study[J]. Lancet Glob Health, 2023, 11(5): e684-e692. [9] STUCK L, KLINKENBERG E, ABDELGADIR ALI N, et al.Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis[J]. Lancet Infect Dis, 2024, 24(7): 726-736. [10] NGUYEN HV, TIEMERSMA E, NGUYEN NV, et al.Disease Transmission by Patients With Subclinical Tuberculosis[J]. Clin Infect Dis, 2023, 76(11): 2000-2006. [11] KlINKENBERG E, FLOYD S, SHANAUBE K, et al. Tuberculosis prevalence after 4 years of population-wide systematic TB symptom screening and universal testing and treatment for HIV in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: A cross-sectional survey (TREATS)[J]. PLoS Med, 2023, 20(9): e1004278. [12] YOON C, DOWDY DW, ESMAIL H, et al.Screening for tuberculosis: time to move beyond symptoms[J]. Lancet Respir Med, 2019, 7(3): 202-204. [13] SOSSEN B, MAARTENS G.Tuberculosis screening in adults with HIV: beyond symptoms[J]. Lancet Glob Health, 2024, 12(5): e719-e720. [14] WORLD HEALTH ORGANIZATION. WHO consolidated guidelines on tuberculosis. Module 2: screening - systematic screening for tuberculosis disease[EB/OL]. (2021-03-22)[2025-12-17]. https://www.who.int/publications/i/item/9789240022676. [15] TAN Q, HUANG CC, BECERRA MC, et al.Chest Radiograph Screening for Detecting Subclinical Tuberculosis in Asymptomatic Household Contacts, Peru[J]. Emerg Infect Dis, 2024, 30(6): 1115-1124. [16] GOLUB JE, MOHAN CI, COMSTOCK GW, et al.Active case finding of tuberculosis: historical perspective and future prospects[J]. Int J Tuberc Lung Dis, 2005, 9(11): 1183-1203. [17] MACPHERSON P, STAGG HR, SCHWALB A, et al.Impact of active case finding for tuberculosis with mass chest X-ray screening in Glasgow, Scotland, 1950-1963: An epidemiological analysis of historical data[J]. PLoS Med, 2024, 21(11): e1004448. [18] BAILY GV, SAVIC D, GOTHI GD, et al.Potential yield of pulmonary tuberculosis cases by direct microscopy of sputum in a district of South India[J]. Bull World Health Organ, 1967, 37(6): 875-892. [19] AZADI D, MOTALLEBIRAD T, GHAFFARI K, et al.Mycobacteriosis and Tuberculosis: Laboratory Diagnosis[J]. Open Microbiol J, 2018, 12: 41-58. [20] CALLIGARO GL, ZIJENAH LS, PETER JG, et al.Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial[J]. Lancet Infect Dis, 2017, 17(4): 441-450. [21] ESMAIL A, RANDALL P, OELOFSE S, et al.Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trial[J]. Nat Med, 2023, 29(4): 1009-1016. [22] DELOGU G, SALI M, FADDA G.The biology of mycobacterium tuberculosis infection[J]. Mediterr J Hematol Infect Dis, 2013, 5(1): e2013070. [23] WORLD HEALTH ORGANIZATION. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection[EB/OL]. (2024-03-20)[2025-12-17]. https://www.who.int/publications/i/item/9789240089488. [24] 中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断 [J/CD]. 新发传染病电子杂志, 2018, 3(1): 59-61. [25] KEMPKER RR, CHKHARTISHVILI N, KINKLADZE I, et al. High Yield of Active Tuberculosis Case Finding Among HIV-Infected Patients Using Xpert MTB/RIF Testing[J]. Open Forum Infect Dis, 2019, 6(6): ofz233. [26] LONG Q, GUO L, JIANG W, et al.Ending tuberculosis in China: health system challenges[J]. Lancet Public Health, 2021, 6(12): e948-e953. [27] LIU K, PENG Y, ZHOU Q, et al.Assessment of active tuberculosis findings in the eastern area of China: A 3-year sequential screening study[J]. Int J Infect Dis, 2019, 88: 34-40. [28] KENDALL EA, KITONSA PJ, NALUTAAYA A, et al.Decline in prevalence of tuberculosis following an intensive case finding campaign and the COVID-19 pandemic in an urban Ugandan community[J]. Thorax, 2024, 79(4): 325-331. [29] MARKS GB, NGUYEN NV, NGUYEN PTB, et al.Community-wide Screening for Tuberculosis in a High-Prevalence Setting[J]. N Engl J Med, 2019, 381(14): 1347-1357. [30] NGWIRA LG, CORBETT EL, KHUNDI M, et al.Screening for Tuberculosis With Xpert MTB/RIF Assay Versus Fluorescent Microscopy Among Adults Newly Diagnosed With Human Immunodeficiency Virus in Rural Malawi: A Cluster Randomized Trial (Chepetsa)[J]. Clin Infect Dis, 2019, 68(7): 1176-1183. [31] Lawn SD, Brooks SV, Kranzer K, et al.Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study[J]. PLoS Med, 2011, 8(7): e1001067. [32] PIVETTA DE ARAUJO RC, MARTINEZ L, DA SILVA SANTOS A, et al. Serial Mass Screening for Tuberculosis Among Incarcerated Persons in Brazil[J]. Clin Infect Dis, 2024, 78(6): 1669-1676. [33] KONTSEVAYA I, CABIBBE AM, CIRILLO DM, et al.Update on the diagnosis of tuberculosis[J]. Clin Microbiol Infect, 2024, 30(9): 1115-1122. [34] KERKHOFF AD, MUYOYETA M, CATTAMANCHI A.Community-wide Screening for Tuberculosis[J]. N Engl J Med, 2020, 382(12): 1185-1186. [35] NTINGINYA EN, SQUIRE SB, MILLINGTON KA, et al.Performance of the Xpert® MTB/RIF assay in an active case-finding strategy: a pilot study from Tanzania[J]. Int J Tuberc Lung Dis, 2012, 16(11): 1468-1470. [36] TANG P, LIU R, QIN L, et al.Accuracy of Xpert® MTB/RIF Ultra test for posterior oropharyngeal saliva for the diagnosis of paucibacillary pulmonary tuberculosis: a prospective multicenter study[J]. Emerg Microbes Infect, 2023, 12(1): 2148564. [37] STEADMAN A, KUMAR KM, ASEGE L, et al.Diagnostic accuracy of swab-based molecular tests for tuberculosis using near-point-of-care platforms: a multi-country evaluation[J]. BioMed, 2025, 121: 105991. [38] ZENG J, HUANG H, LIU X, et al.Pooling sputum samples for the Xpert MTB/RIF assay: a practical screening strategy for highly infectious tuberculosis cases[J]. BMC Infect Dis, 2024, 24(1): 122. [39] 刘淑媛, 李凯文, 王星皓等. C反应蛋白电化学免疫传感器的研究进展[J]. 分析试验室, 2023, 42(11): 1552-1562. [40] RUPEREZ M, SHANAUBE K, MUREITHI L, et al.Use of point-of-care C-reactive protein testing for screening of tuberculosis in the community in high-burden settings: a prospective, cross-sectional study in Zambia and South Africa[J]. Lancet Glob Health, 2023, 11(5): e704-e714. [41] SINGHANIA A, WILKINSON RJ, RODRIGUE M, et al.The value of transcriptomics in advancing knowledge of the immune response and diagnosis in tuberculosis[J]. Nat Immunol, 2018, 19(11): 1159-1168. [42] MOREIRA FMF, VERMA R, PEREIRA DOS SANTOS PC, et al. Blood-based host biomarker diagnostics in active case finding for pulmonary tuberculosis: A diagnostic case-control study[J]. Clin Med, 2021, 33: 100776. [43] TURNER CT, GUPTA RK, TSALIKI E, et al.Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study[J]. Lancet Respir Med, 2020, 8(4): 407-419. [44] ZHANG S, BEI C, LI M, et al.Identification and evaluation of blood transcriptional biomarker for tuberculosis screening[J]. Int J Infect Dis, 2025, 153: 107838. [45] CODLIN AJ, DAO TP, VO LNQ, et al.Independent evaluation of 12 artificial intelligence solutions for the detection of tuberculosis[J]. Sci Rep, 2021, 11(1): 23895. [46] TAVAZIVA G, HARRIS M, ABIDI SK, et al.Chest X-ray Analysis With Deep Learning-Based Software as a Triage Test for Pulmonary Tuberculosis: An Individual Patient Data Meta-Analysis of Diagnostic Accuracy[J]. Clin Infect Dis, 2022, 74(8): 1390-1400. [47] LI P, WANG J, TANG M, et al.A CT-based radiomics predictive nomogram to identify pulmonary tuberculosis from community-acquired pneumonia: a multicenter cohort study[J]. Front Cell Infect Microbiol, 2024, 14: 1388991. [48] SHEN MT, LIU X, GAO Y, et al. Radiomics-based quantitative contrast-enhanced CT analysis of abdominal lymphadenopathy to differentiate tuberculosis from lymphoma[J]. Precis Clin Med, 2024, 7(1): pbae002. [49] YANG L, JIANG Z, TONG J, et al.Development and validation of a preoperative CT-based radiomics nomogram to differentiate tuberculosis granulomas from lung adenocarcinomas: an external validation study[J]. BMC Cancer, 2024, 24(1): 670. [50] ZHOU L, WANG Y, ZHU W, et al.A retrospective study differentiating nontuberculous Mycobacterial pulmonary disease from pulmonary tuberculosis on computed tomography using radiomics and machine learning algorithms[J]. Ann Med, 2024, 56(1): 2401613. [51] LI Y, WANG B, WEN L, et al.Machine learning and radiomics for the prediction of multidrug resistance in cavitary pulmonary tuberculosis: a multicentre study[J]. Eur Radiol, 2023, 33(1): 391-400. [52] LI Y, XU Z, LV X, et al.Radiomics analysis of lung CT for multidrug resistance prediction in active tuberculosis: a multicentre study[J]. Eur Radiol, 2023, 33(9): 6308-6317. [53] ZHANG X, DONG Z, LI H, et al.Development and validation of a deep learning ultrasound radiomics model for predicting drug resistance in lymph node tuberculosis a multicenter study[J]. Int J Surg, 2025, 111(10): 6627-6637. [54] DU PLESSIS T, RAE W, RAMKILAWON G, et al.Quantitative Chest X-ray Radiomics for Therapy Response Monitoring in Patients with Pulmonary Tuberculosis[J]. Diagnostics (Basel), 2023, 13(17). [55] NIJIATI M, GUO L, ABULIZI A, et al.Deep learning and radiomics of longitudinal CT scans for early prediction of tuberculosis treatment outcomes[J]. Eur J Radiol, 2023, 169: 111180. [56] LU MY, CHEN B, WILLIAMSON DFK, et al.A multimodal generative AI copilot for human pathology[J]. Nature, 2024, 634(8033): 466-473. [57] PARK HJ, HUH JY, CHAE G, et al.Extraction of clinical data on major pulmonary diseases from unstructured radiologic reports using a large language model[J]. PLoS One, 2024, 19(11): e0314136. [58] FINK MA, BISCHOFF A, FINK CA, et al.Potential of ChatGPT and GPT-4 for Data Mining of Free-Text CT Reports on Lung Cancer[J]. Radiology, 2023, 308(3): e231362. |